David J Cote1,2,3, John L Kilgallon3, Noah L A Nawabi3, Hassan Y Dawood3, Timothy R Smith2,3, Ursula B Kaiser2,4, Edward R Laws2, JoAnn E Manson5,6, Meir J Stampfer1,6,7. 1. Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA. 2. Pituitary/Neuroendocrine Center, Department of Neurosurgery, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA. 3. Computational Neuroscience Outcomes Center, Department of Neurosurgery, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA. 4. Division of Endocrinology, Diabetes, and Hypertension, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA. 5. Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA. 6. Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, Massachusetts 02115, USA. 7. Department of Nutrition, Harvard T. H. Chan School of Public Health, Boston, Massachusetts 02115, USA.
Abstract
CONTEXT: No prospective epidemiologic studies have examined associations between use of oral contraceptives (OCs) or menopausal hormone therapy (MHT) and risk of pituitary adenoma in women. OBJECTIVE: Our aim was to determine the association between use of OC and MHT and risk of pituitary adenoma in two separate datasets. METHODS: We evaluated the association of OC/MHT with risk of pituitary adenoma in the Nurses' Health Study and Nurses' Health Study II by computing multivariable-adjusted hazard ratios (MVHR) of pituitary adenoma by OC/MHT use using Cox proportional hazards models. Simultaneously, we carried out a matched case-control study using an institutional data repository to compute multivariable-adjusted odds ratios (MVOR) of pituitary adenoma by OC/MHT use. RESULTS: In the cohort analysis, during 6 668 019 person-years, 331 participants reported a diagnosis of pituitary adenoma. Compared to never-users, neither past (MVHR = 1.05; 95% CI, 0.80-1.36) nor current OC use (MVHR = 0.72; 95% CI, 0.40-1.32) was associated with risk. For MHT, compared to never-users, both past (MVHR = 2.00; 95% CI, 1.50-2.68) and current use (MVHR = 1.80; 95% CI, 1.27-2.55) were associated with pituitary adenoma risk, as was longer duration (MVHR = 2.06; 95% CI, 1.42-2.99 comparing more than 5 years of use to never, P trend = .002). Results were similar in lagged analyses, when stratified by body mass index, and among those with recent health care use. In the case-control analysis, we included 5469 cases. Risk of pituitary adenoma was increased with ever use of MHT (MVOR = 1.57; 95% CI, 1.35-1.83) and OC (MVOR = 1.27; 95% CI, 1.14-1.42) compared to never. CONCLUSION: Compared to never use, current and past MHT use and longer duration of MHT use were positively associated with higher risk of pituitary adenoma in 2 independent data sets. OC use was not associated with risk in the prospective cohort analysis and was associated with only mildly increased risk in the case-control analysis.
CONTEXT: No prospective epidemiologic studies have examined associations between use of oral contraceptives (OCs) or menopausal hormone therapy (MHT) and risk of pituitary adenoma in women. OBJECTIVE: Our aim was to determine the association between use of OC and MHT and risk of pituitary adenoma in two separate datasets. METHODS: We evaluated the association of OC/MHT with risk of pituitary adenoma in the Nurses' Health Study and Nurses' Health Study II by computing multivariable-adjusted hazard ratios (MVHR) of pituitary adenoma by OC/MHT use using Cox proportional hazards models. Simultaneously, we carried out a matched case-control study using an institutional data repository to compute multivariable-adjusted odds ratios (MVOR) of pituitary adenoma by OC/MHT use. RESULTS: In the cohort analysis, during 6 668 019 person-years, 331 participants reported a diagnosis of pituitary adenoma. Compared to never-users, neither past (MVHR = 1.05; 95% CI, 0.80-1.36) nor current OC use (MVHR = 0.72; 95% CI, 0.40-1.32) was associated with risk. For MHT, compared to never-users, both past (MVHR = 2.00; 95% CI, 1.50-2.68) and current use (MVHR = 1.80; 95% CI, 1.27-2.55) were associated with pituitary adenoma risk, as was longer duration (MVHR = 2.06; 95% CI, 1.42-2.99 comparing more than 5 years of use to never, P trend = .002). Results were similar in lagged analyses, when stratified by body mass index, and among those with recent health care use. In the case-control analysis, we included 5469 cases. Risk of pituitary adenoma was increased with ever use of MHT (MVOR = 1.57; 95% CI, 1.35-1.83) and OC (MVOR = 1.27; 95% CI, 1.14-1.42) compared to never. CONCLUSION: Compared to never use, current and past MHT use and longer duration of MHT use were positively associated with higher risk of pituitary adenoma in 2 independent data sets. OC use was not associated with risk in the prospective cohort analysis and was associated with only mildly increased risk in the case-control analysis.
Authors: Joseph Biederman; Ronna Fried; Maura DiSalvo; K Yvonne Woodworth; Itai Biederman; Haley Driscoll; Elizabeth Noyes; Stephen V Faraone; Roy H Perlis Journal: Psychopharmacology (Berl) Date: 2020-06-26 Impact factor: 4.530
Authors: Stephanie A Smith-Warner; Donna Spiegelman; John Ritz; Demetrius Albanes; W Lawrence Beeson; Leslie Bernstein; Franco Berrino; Piet A van den Brandt; Julie E Buring; Eunyoung Cho; Graham A Colditz; Aaron R Folsom; Jo L Freudenheim; Edward Giovannucci; R Alexandra Goldbohm; Saxon Graham; Lisa Harnack; Pamela L Horn-Ross; Vittorio Krogh; Michael F Leitzmann; Marjorie L McCullough; Anthony B Miller; Carmen Rodriguez; Thomas E Rohan; Arthur Schatzkin; Roy Shore; Mikko Virtanen; Walter C Willett; Alicja Wolk; Anne Zeleniuch-Jacquotte; Shumin M Zhang; David J Hunter Journal: Am J Epidemiol Date: 2006-04-19 Impact factor: 4.897
Authors: Ying Bao; Monica L Bertoia; Elizabeth B Lenart; Meir J Stampfer; Walter C Willett; Frank E Speizer; Jorge E Chavarro Journal: Am J Public Health Date: 2016-07-26 Impact factor: 9.308
Authors: Wendy Y Chen; Graham A Colditz; Bernard Rosner; Susan E Hankinson; David J Hunter; JoAnn E Manson; Meir J Stampfer; Walter C Willett; Frank E Speizer Journal: Ann Intern Med Date: 2002-11-19 Impact factor: 25.391
Authors: Shilpa N Bhupathiraju; Francine Grodstein; Meir J Stampfer; Walter C Willett; Frank B Hu; JoAnn E Manson Journal: Am J Public Health Date: 2016-07-26 Impact factor: 9.308
Authors: Yang Hu; Karen H Costenbader; Xiang Gao; May Al-Daabil; Jeffrey A Sparks; Daniel H Solomon; Frank B Hu; Elizabeth W Karlson; Bing Lu Journal: Am J Clin Nutr Date: 2014-07-16 Impact factor: 7.045